Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.72 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459686 | 1.00 | S1PR1 (0.72) | S1PR1S1PR5S1PR3S1PR4KCNH2 | |
| SCHEMBL16649335 | 0.91 | S1PR1 (0.59) | S1PR1S1PR5S1PR3S1PR4KCNH2 | |
| SCHEMBL460888 | 0.84 | S1PR1 (1.00) | S1PR1S1PR5S1PR3S1PR4KCNH2 | |
| SCHEMBL15023402 | 0.84 | S1PR1 (0.74) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL15023403 | 0.84 | S1PR1 (0.74) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL460887 | 0.84 | S1PR1 (1.00) | S1PR1S1PR5S1PR3S1PR4KCNH2 | |
| SCHEMBL460081 | 0.82 | S1PR1 (0.82) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL460080 | 0.82 | S1PR1 (0.82) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL436579 | 0.82 | S1PR1 (0.73) | S1PR1S1PR5S1PR3S1PR4KCNH2 | |
| SCHEMBL435271 | 0.80 | S1PR1 (0.65) | S1PR1S1PR5S1PR3S1PR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | claimed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | claimed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | claimed |
| EP-2595969-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | claimed |
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| EP-2595969-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR5 4/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.